Investigation using this model has ultimately led to the approval by the Food and Drug Administration of tumor necrosis factor-α (TNF-α) inhibitor as the first targeted, corticosteroid-sparing biologic for treating noninfectious uveitis involving the intermediate or posterior eye.15 Here, TNF is linked to uveitis.